Ceftriaxone is pivotal in treating severe infections; however, predicting unbound plasma ceftriaxone (CEF) from total ceftriaxone (CEF) remains challenging. This study aimed to (1) predict CEF from CEF, (2) determine optimal target for CEF trough concentration in plasma, (3) perform an external validation of published models, and (4) to ascertain whether the CEF dosing regimen was sufficient to achieve the therapeutic objectives. CEF predictions based on CEF were evaluated using previously published models.
View Article and Find Full Text PDF